South Korea
· Delayed Price · Currency is KRW ABL Bio Statistics
Total Valuation
ABL Bio has a market cap or net worth of KRW 1.95 trillion. The enterprise value is 1.95 trillion.
| Market Cap | 1.95T |
| Enterprise Value | 1.95T |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABL Bio has 48.05 million shares outstanding. The number of shares has increased by 0.29% in one year.
| Shares Outstanding | 48.05M |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 30.55% |
| Owned by Institutions (%) | 20.50% |
| Float | 33.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.87 |
| PB Ratio | 36.61 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -48.87 |
| EV / Sales | 59.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -26.60 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.82.
| Current Ratio | 1.55 |
| Quick Ratio | 1.48 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.59 |
| Interest Coverage | -48.12 |
Financial Efficiency
Return on equity (ROE) is -56.84% and return on invested capital (ROIC) is -22.70%.
| Return on Equity (ROE) | -56.84% |
| Return on Assets (ROA) | -16.60% |
| Return on Capital (ROIC) | -22.70% |
| Revenue Per Employee | 323.08M |
| Profits Per Employee | -392.18M |
| Employee Count | 102 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +103.52% |
| 50-Day Moving Average | 30,821.00 |
| 200-Day Moving Average | 25,684.25 |
| Relative Strength Index (RSI) | 74.87 |
| Average Volume (20 Days) | 1,740,225 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABL Bio had revenue of KRW 32.95 billion and -40.00 billion in losses. Loss per share was -835.12.
| Revenue | 32.95B |
| Gross Profit | 32.89B |
| Operating Income | -40.95B |
| Pretax Income | -40.00B |
| Net Income | -40.00B |
| EBITDA | -38.42B |
| EBIT | -40.95B |
| Loss Per Share | -835.12 |
Balance Sheet
The company has 34.51 billion in cash and 43.47 billion in debt, giving a net cash position of -8.96 billion or -186.49 per share.
| Cash & Cash Equivalents | 34.51B |
| Total Debt | 43.47B |
| Net Cash | -8.96B |
| Net Cash Per Share | -186.49 |
| Equity (Book Value) | 53.16B |
| Book Value Per Share | 1,106.30 |
| Working Capital | 12.76B |
Cash Flow
In the last 12 months, operating cash flow was -64.89 billion and capital expenditures -8.59 billion, giving a free cash flow of -73.49 billion.
| Operating Cash Flow | -64.89B |
| Capital Expenditures | -8.59B |
| Free Cash Flow | -73.49B |
| FCF Per Share | -1,529.44 |
Margins
Gross margin is 99.81%, with operating and profit margins of -124.25% and -121.39%.
| Gross Margin | 99.81% |
| Operating Margin | -124.25% |
| Pretax Margin | -121.39% |
| Profit Margin | -121.39% |
| EBITDA Margin | -116.60% |
| EBIT Margin | -124.25% |
| FCF Margin | -222.99% |
Dividends & Yields
ABL Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | -0.29% |
| Earnings Yield | -2.06% |
| FCF Yield | -3.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABL Bio has an Altman Z-Score of 4.12.
| Altman Z-Score | 4.12 |
| Piotroski F-Score | n/a |